Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.

Autor:	Gordon R; School of Biomedical Sciences, Faculty of Medicine, University of Queensland, St Lucia, Queensland 4072, Australia.; UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Queensland 4092, Australia., Albornoz EA; School of Biomedical Sciences, Faculty of Medicine, University of Queensland, St Lucia, Queensland 4072, Australia.; Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland 4072, Australia., Christie DC; School of Biomedical Sciences, Faculty of Medicine, University of Queensland, St Lucia, Queensland 4072, Australia., Langley MR; Parkinson Disorders Research Program, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA., Kumar V; School of Biomedical Sciences, Faculty of Medicine, University of Queensland, St Lucia, Queensland 4072, Australia., Mantovani S; UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Queensland 4092, Australia.; Department of Neurology, Royal Brisbane and Women's Hospital, Herston, Queensland 4006, Australia., Robertson AAB; Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland 4072, Australia.; School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland 4072, Australia., Butler MS; Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland 4072, Australia., Rowe DB; Department of Neurology, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia., O'Neill LA; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Dublin 2, Ireland., Kanthasamy AG; Parkinson Disorders Research Program, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA., Schroder K; Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland 4072, Australia., Cooper MA; Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland 4072, Australia. t.woodruff@uq.edu.au m.cooper@uq.edu.au.; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Dublin 2, Ireland., Woodruff TM; School of Biomedical Sciences, Faculty of Medicine, University of Queensland, St Lucia, Queensland 4072, Australia. t.woodruff@uq.edu.au m.cooper@uq.edu.au.
Jazyk:	angličtina
Zdroj:	Science translational medicine [Sci Transl Med] 2018 Oct 31; Vol. 10 (465).
DOI:	10.1126/scitranslmed.aah4066
Abstrakt:	Parkinson's disease (PD) is characterized by a profound loss of dopaminergic neurons in the substantia nigra, accompanied by chronic neuroinflammation, mitochondrial dysfunction, and widespread accumulation of α-synuclein-rich protein aggregates in the form of Lewy bodies. However, the mechanisms linking α-synuclein pathology and dopaminergic neuronal death to chronic microglial neuroinflammation have not been completely elucidated. We show that activation of the microglial NLR family pyrin domain containing 3 (NLRP3) inflammasome is a common pathway triggered by both fibrillar α-synuclein and dopaminergic degeneration in the absence of α-synuclein aggregates. Cleaved caspase-1 and the inflammasome adaptor protein apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC) were elevated in the substantia nigra of the brains of patients with PD and in multiple preclinical PD models. NLRP3 activation by fibrillar α-synuclein in mouse microglia resulted in a delayed but robust activation of the NLRP3 inflammasome leading to extracellular interleukin-1β and ASC release in the absence of pyroptosis. Nanomolar doses of a small-molecule NLRP3 inhibitor, MCC950, abolished fibrillar α-synuclein-mediated inflammasome activation in mouse microglial cells and extracellular ASC release. Furthermore, oral administration of MCC950 in multiple rodent PD models inhibited inflammasome activation and effectively mitigated motor deficits, nigrostriatal dopaminergic degeneration, and accumulation of α-synuclein aggregates. These findings suggest that microglial NLRP3 may be a sustained source of neuroinflammation that could drive progressive dopaminergic neuropathology and highlight NLRP3 as a potential target for disease-modifying treatments for PD. (Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu